Journal of Clinical Pediatrics >
Acute lymphoblastic leukemia with chemotherapy-related cerebral lesion: clinical and imaging features
Received date: 2024-03-26
Accepted date: 2024-07-29
Online published: 2025-01-03
Objective To investigate the types, clinical and imaging features and prognosis of chemotherapy-related cerebral lesion in acute lymphoblastic leukemia (ALL), so as to improve the clinicians' understanding of this kind of brain injury. Methods The clinical data of children with ALL who developed chemotherapy-related cerebral lesion after receiving chemotherapy alone from June 2015 to June 2023 were retrospectively analyzed. Results A total of 46 children (24 boys and 22 girls) with chemotherapy-related cerebral lesion were enrolled. The median onset age of ALL was 5.6(3.7-10.2) years old. The median age of children with cerebral lesion treated by chemotherapy was 6.6(4.7-10.3) years old. First cerebral lesion occurred 2.0(1.0-8.0) months after the first systemic chemotherapy, including 34 cases (73.9%) of encephalopathy, 9 cases (19.6%) of neurovascular complications, and 3 cases (6.5%) of isolated neurological symptoms. Neurological symptoms occurred in 38 children. Seizures were the most common (26 cases), followed by dizziness or headache, paralysis, visual disturbance, etc. The lesions in children with encephalopathy were mainly distributed around the lateral ventricles, semi-oval center, the parietal lobe, the occipital lobe, and the frontal lobe. The main neurovascular complications were intracranial hemorrhage and cerebral thrombosis, among which the superior sagittal sinus was the most common site of venous thrombosis.Among 38 patients with obvious neurological symptoms, 30 patients showed rapid improvement in clinical manifestations and had a good prognosis. At the follow-up of 22 months, 29 of the 32 children with neuroimaging abnormalities showed improvement after review. Conclusions The clinical and neuroimaging manifestations of ALL with chemotherapy-related cerebral lesion were diverse, and the overall prognosis was good. Few children had symptomatic epilepsy sequelae. Early neuroimaging is helpful for early detection and intervention of cerebral lesion and better optimization of ALL treatment.
ZHAO Min , TANG Jihong , XIAO Xiao , YANG Letian , XU Huan , WU Yinyin , FENG Juan . Acute lymphoblastic leukemia with chemotherapy-related cerebral lesion: clinical and imaging features[J]. Journal of Clinical Pediatrics, 2025 , 43(1) : 14 -20 . DOI: 10.12372/jcp.2025.24e0261
[1] | Jeha S, Pei D, Choi J, et al. Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude total therapy study 16[J]. J Clin Oncol, 2019, 37(35): 3377-3391. |
[2] | Taillibert S, Le Rhun E, Chamberlain MC. Chemotherapy-related neurotoxicity[J]. Curr Neurol Neurosci Rep, 2016, 16(9): 81. |
[3] | Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate chemotherapy induces persistent tri-glial dysregulation that underlies chemotherapy-related cognitive impairment[J]. Cell, 2019, 176(1-2): 43-55. |
[4] | Lenfant C, Greiner N, Duprez T. Cytarabine-induced encephalitis[J]. J Belg Soc Radiol, 2021, 105(1): 46. |
[5] | Newey CR, Chandrasekaran PN, Mohebbi MR. Posterior reversible encephalopathy syndrome after high-dose cytarabine in acute myelogenous leukemia[J]. Neurol India, 2017, 65(1): 220. |
[6] | Abaji R, Krajinovic M. Pharmacogenetics of asparaginase in acute lymphoblastic leukemia[J]. Cancer Drug Resist, 2019, 2(2): 242-255. |
[7] | Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy[J]. Blood Rev, 2015, 29(2): 93-100. |
[8] | 吴晔. 儿童脑白质病变的识别及诊断[J]. 北京医学, 2018, 40(7): 614-615. |
Wu Y. Identification and diagnosis of white matter lesions in children[J]. Beijing Yikue, 2018, 40(7): 614-615. | |
[9] | 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议(第四次修订)[J]. 中华儿科杂志, 2014, 52(9): 641-644. |
Hematology Group of pediatric Society of Chinese Medical Association, Editorial Board of Chinese Journal of Pediatrics. Recommendations for diagnosis and treatment of childhood acute lymphoblastic leukemia (the fourth revision)[J]. Zhonghua Erke Zazhi, 2014, 52(9): 641-644. | |
[10] | Conklin HM, Krull KR, Reddick WE, et al. Cognitive outcomes following contemporary treatment without cranial irradiation for childhood acute lymphoblastic leukemia[J]. J Natl Cancer Inst, 2012, 104(18): 1386-1395. |
[11] | Cao SC, Legerstee JS, van Bellinghen M, et al. Effect of chemotherapy (with and without radiotherapy) on the intelligence of children and adolescents treated for acute lymphoblastic leukemia; a meta-analysis[J]. Psychooncology, 2023, 32(4): 492-505. |
[12] | Jacola LM, Conklin HM, Krull KR, et al. The impact of intensified CNS-directed therapy on neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia treated without cranial irradiation[J]. J Clin Oncol, 2022, 40(36): 4218-4227. |
[13] | Krull KR, Cheung YT, Liu W, et al. Chemotherapy pharmacodynamics and neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia[J]. J Clin Oncol, 2016, 34(22): 2644-2653. |
[14] | ?liwa-Tytko P, Kaczmarska A, Lejman M, et al. Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy[J]. Int J Mol Sci, 2022, 23(10): 5515. |
[15] | Sainz de la Maza Cantero S, Jiménez Martín A, de Felipe Mimbrera A, et al. Cerebellar toxicity due to cytarabine: a series of 4 cases[J]. Neurologia, 2016, 31(7): 491-492. |
[16] | Drachtman RA, Cole PD, Golden CB, et al. Dex-tromethorphan is effective in the treatment of subacute methotrexate neurotoxicity[J]. Pediatr Hematol Oncol, 2002, 19(5): 319-327. |
[17] | Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency[J]. J Clin Oncol, 1997, 15(2): 833-839. |
[18] | Partap S, Russo S, Esfahani B, et al. A review of chronic leukoencephalopathy among survivors of childhood cancer[J]. Pediatr Neurol, 2019, 101: 2-10. |
[19] | Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients[J]. Blood, 2006, 108(7): 2216-2222. |
[20] | Kieslich M, Porto L, Lanfermann H, et al. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia[J]. J Pediatr Hematol Oncol, 2003, 25(6): 484-487. |
[21] | Goyal G, Bhatt VR. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia[J]. Future Oncol, 2015, 11(17): 2459-2470. |
[22] | Alessi I, Caroleo AM, de Palma L, et al. Short and long-term toxicity in pediatric cancer treatment: central nervous system damage[J]. Cancers (Basel), 2022, 14(6): 1540. |
[23] | Kim KH, Park M, Park EY, et al. Disseminating necrotizing leukoencephalopathy associated with intra-CSF methotrexate chemotherapy: a retrospective observational study[J]. Neurology, 2024, 102(5): e209167. |
/
〈 |
|
〉 |